Skip to content
value.today

Onconova Therapeutics Inc.

Total raised
$107 M
4 rounds on record
Latest round
$50 M
Jul 2012
First round on record
May 2009
Today
Went public
See the company page

Onconova Therapeutics Inc. is listed today as Traws Pharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Onconova Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2018$1 MPrivate placement after listingUnder $2 million

Onconova Therapeutics Inc.: Private sale, Apr 2018

Investors in this round

1 investor had bought by the notice of Jun 8, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,250,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$75,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Manoj M. Maniar · Executive Officer
  • Mark P. Guerin · Executive Officer
  • Ramesh S. Kumar · Executive Officer, Director
  • Steven M. Fruchtman · Executive Officer
  • E. Premkumar J. Reddy · Director
  • Henry S. Bienen · Director
  • Jack E. Stover · Director
  • James J. Marino · Director
  • Jerome E. Groopman · Director
  • Michael B. Hoffman · Director
  • Viren S. Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Lucas Advisors LLC d/b/a KYBORA Emerging Markets · broker-dealer Lucas Advisors LLC d/b/a KYBORA Emerging Markets · Lambertville, New JerseySold in no state named, and outside the US

Signed by Mark P. Guerin, Chief Financial Officer. Newest notice filed Jun 8, 2018. Read the notice at the SEC.

equitySEC
Oct 2015$2 MPrivate placement after listingUnder $2 million

Onconova Therapeutics Inc.: Private sale, Oct 2015

Investors in this round

1 investor had bought by the notice of Oct 23, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $17 M offered; $15 M still to sell
Smallest investment taken
$1,500,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajay M. Bansal · Executive Officer
  • Manoj M. Maniar · Executive Officer
  • Ramesh Kumar, Ph.D · Executive Officer, Director
  • Steven M. Fruchtman · Executive Officer
  • Thomas M. McKearn · Executive Officer
  • Anne M. VanLent · Director
  • E. Premkumar Reddy · Director
  • Henry S Bienen · Director
  • James M. Marino · Director
  • Jerome E. Groopman · Director
  • Michael M. Hoffman · Director
  • Viren E. Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used for general corporate purposes, which may include payment of executive salaries.”

Signed by Ajay Bansal, Chief Financial Officer. Newest notice filed Oct 23, 2015. Read the notice at the SEC.

equitySEC
Jul 2012$50 MNo. 4$50 to $250 million

Onconova Therapeutics Inc.: Raise no. 4, Jul 2012

Investors in this round

1 investor had bought by the notice of Aug 13, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
$49,999,999
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • E. Premkumar Reddy, Ph.D · Executive Officer, Director
  • Ramesh Kumar, Ph.D · Executive Officer, Director
  • Alan R. Williamson · Director
  • Henry S. Bienen · Director
  • K. R. Ravindra · Director
  • Michael R. Hoffman · Director
  • Pankaj R. Patel · Director
  • Shekhar S. Kundur · Director
  • Viren R. Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aquilo Partners, L.P. (CRD 114909) · San Francisco, CaliforniaSold in IL

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital and general corporate purposes.”

Signed by Ramesh Kumar, Ph.D, President. Newest notice filed Aug 13, 2012. Read the notice at the SEC.

equitySEC
Apr 2012$26 MNo. 3$10 to $50 million

Onconova Therapeutics Inc.: Raise no. 3, Apr 2012

Investors in this round

41 investors had bought by the notice of Jul 26, 2012: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $30 M offered; $4 M still to sell
Smallest investment taken
$1,000
What was sold
equity, options or other rights to buy securities, other: Convertible Promissory Notes, convertible into Series I Preferred Stock, under certain circumstances.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • E. Premkumar Reddy, Ph.D. · Executive Officer, Director
  • Ramesh Kumar, Ph.D. · Executive Officer, Director
  • Alan R. Williamson · Director
  • Henry S. Bienen · Director
  • K. R. Ravindra · Director
  • Michael R. Hoffman · Director
  • Pankaj R. Patel · Director
  • Viren R. Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital and general corporate purposes.”

Signed by Ramesh Kumar, Ph.D., President. Newest notice filed Jul 26, 2012 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Sep 2010$12 MNo. 2$10 to $50 million

Onconova Therapeutics Inc.: Raise no. 2, Sep 2010

Investors in this round

67 investors had bought by the notice of Jan 5, 2011: 67 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $20 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • E. Premkumar Reddy, Ph.D. · Executive Officer, Director
  • Ramesh Kumar, Ph.D. · Executive Officer, Director
  • Alan R. Williamson · Director
  • Henry B. Binen · Director
  • K. R. Ravindra · Director
  • Michael R. Hoffman · Director
  • Pankaj R. Patel · Director
  • Viren R. Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital and general corporate purposes”

Signed by Ramesh Kumar, Ph.D., President. Newest notice filed Jan 5, 2011 (1 amendment). Read the notice at the SEC.

equitySEC
May 2009$19 MNo. 1$10 to $50 million

Onconova Therapeutics Inc.: Raise no. 1, May 2009

Investors in this round

58 investors had bought by the notice of Mar 4, 2010: 58 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $26 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • E. Premkumar Reddy, Ph.D. · Executive Officer, Director
  • Ramesh Kumar, Ph.D. · Executive Officer, Director
  • Alan R. Williamson · Director
  • Henry S. Bienen, Ph.D. · Director
  • K R. Ravindra · Director
  • Michael B. Hoffman · Director
  • Pankaj S. Patel · Director
  • Viren R. Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount reflects the purchase price of the Series G Convertible Preferred Stock and warrants to purchase shares of Series G Convertible Preferred Stock, and the exercise price of the warrants.”
  • On the use of proceeds: “Proceeds to be used for working capital and other general corporate purposes, which include salaries payable in the ordinary course of business.”

Signed by Ramesh Kumar, Ph.D., President. Newest notice filed Mar 4, 2010 (1 amendment). Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Traws Pharma, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $2.79 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Onconova Therapeutics Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Jun 2018).

    SEC Form D (revenue range) · Jun 2018

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2010; revenue between $1 million and $5 million in 2011; revenue between $5 million and $25 million in 2012; revenue of up to $1 million in 2018.

    SEC Form D (revenue range) · Jun 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2018

Products and services#

No products or services of Onconova Therapeutics Inc. are on record.

Investors#

No investor of Onconova Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Traws Pharma, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Onconova Therapeutics Inc.
NameRoleNamed in
Manoj M. ManiarExecutive officerJun 2018
Mark P. GuerinExecutive officerJun 2018
Ramesh S. KumarExecutive officerJun 2018
Steven M. FruchtmanExecutive officerJun 2018
Ajay M. BansalExecutive officerOct 2015
Ramesh Kumar, Ph.DExecutive officerOct 2015
Thomas M. McKearnExecutive officerOct 2015
E. Premkumar Reddy, Ph.DExecutive officerAug 2012
E. Premkumar Reddy, Ph.D.Executive officerJul 2012
Ramesh Kumar, Ph.D.Executive officerJul 2012
E. Premkumar J. ReddyDirectorJun 2018
Henry S. BienenDirectorJun 2018
Jack E. StoverDirectorJun 2018
James J. MarinoDirectorJun 2018
Jerome E. GroopmanDirectorJun 2018
Michael B. HoffmanDirectorJun 2018
Ramesh S. KumarDirectorJun 2018
Viren S. MehtaDirectorJun 2018
Anne M. VanLentDirectorOct 2015
E. Premkumar ReddyDirectorOct 2015
Henry S BienenDirectorOct 2015
James M. MarinoDirectorOct 2015
Michael M. HoffmanDirectorOct 2015
Ramesh Kumar, Ph.DDirectorOct 2015
Viren E. MehtaDirectorOct 2015
Alan R. WilliamsonDirectorAug 2012
E. Premkumar Reddy, Ph.DDirectorAug 2012
K. R. RavindraDirectorAug 2012
Michael R. HoffmanDirectorAug 2012
Pankaj R. PatelDirectorAug 2012
Shekhar S. KundurDirectorAug 2012
Viren R. MehtaDirectorAug 2012
E. Premkumar Reddy, Ph.D.DirectorJul 2012
Ramesh Kumar, Ph.D.DirectorJul 2012
Henry B. BinenDirectorJan 2011
Henry S. Bienen, Ph.D.DirectorMar 2010
K R. RavindraDirectorMar 2010
Pankaj S. PatelDirectorMar 2010
K RavindraDirectorMay 2009
Pankaj PatelDirectorMay 2009

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.